Long-Term Efficacy and Safety of Linagliptin in Patients With
Type 2 Diabetes and Severe Renal Impairment  A 1-year,
randomized, double-blind, placebo-controlled study    1. Hans-
Juergen Woerle, MD6   1. 1Division of Endocrinology, Metabolism
and Lipid Research, Washington University in St. Louis, St.
Louis, Missouri   2. 2Texas Institute for Kidney and Endocrine
Disorders, Lufkin, Texas   3. 3Boehringer Ingelheim, Ridgefield,
Connecticut   4. 4Boehringer Ingelheim, Bracknell, U.K.   5.
5Boehringer Ingelheim, Reims, France   6. 6Boehringer Ingelheim,
Ingelheim, Germany   1. Corresponding author: Janet B. McGill,
jmcgill{at}dom.wustl.edu.   OBJECTIVE This placebo-controlled
study assessed long-term efficacy and safety of the dipeptidyl
peptidase-4 inhibitor linagliptin in patients with type 2
diabetes and severe renal impairment (RI).  RESEARCH DESIGN AND
METHODS In this 1-year, double-blind study, 133 patients with
type 2 diabetes (HbA1c 7.0–10.0%) and severe RI (estimated
glomerular filtration rate [eGFR] <3